April 6, 2021
CALIXAR and CliniSciences Group finalize a distribution agreement
CALIXAR is proud to announce the beginning of a new distribution agreement with CliniSciences Group, a European distributor.
Under this agreement, CliniSciences Group will promote and distribute CALIXAR’s high-quality membrane protein targets (for antibody development, drug discovery, and vaccine formulation) and customized reagents specifically designed for the extraction and/or stabilization of membrane proteins. By an international visibility of CliniSciences Group, this agreement covers many territories in the world as Europe, USA, Austria, Morocco, and Tunisia.
CliniSciences’ teams have also the ability to support its customers in their projects, involving membrane proteins by providing them CALIXAR’s expertise and services in native isolation and purification of membrane proteins.
About CliniSciences Group
CliniSciences Group commercializes reagents (antibodies, recombinants, ELISA kits, RNAi, cDNA clones, probes, PCR/qPCR reagents...) to diagnostic and research labs. As a very dynamic company, they do their best to be close to customers's needs in terms of high-quality reagents that they propose and in terms of service that they provide (search for a particular antibody, technical support, delivery time, ...).
Their principal assets for better serving their customers: adaptability, flexibility, reactivity and naturally the competence of the technical specialists at your service.
The CliniSciences group has subsidiaries in France and Italy (CliniSciences), Luxembourg (Kyvobio), Germany (Biotrend), Spain (Quimigen), UK (Generon), Morocco (Hexabiogen). Each of these companies can advise and inform you in the local language thanks to a commercial and technical team present in each country.
For more information: https://www.clinisciences.com/